**IN THE CLAIMS:**

Please cancel claims 13-16, without prejudice or disclaimer. In accordance with 37 CFR § 1.121, please substitute for original claims 1, 8, 9, 17, and 18, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Marked Up Version Showing Changes Made." Please add claims 19-36.

B1

1. (Once amended) A pharmaceutical formulation comprising human parathyroid hormone at a concentration of 0.3 mg/ml to 10 mg/ml; a pharmaceutically acceptable buffer having a pH from 4 to 6, and at least one tonicity modifier that is NaCl.

B2

8. (Once amended) The formulation according to claim 1, further comprising a second tonicity modifier that is mannitol.

9. (Twice amended) A pharmaceutical formulation comprising 1 to 3 mg/ml parathyroid hormone, 2 to 5 mg/ml NaCl, 20 to 50 mg/ml mannitol, and 5 to 10 mM citrate buffer at a pH between 4 and 6.

B3

17. (Twice amended) A method for treating a bone related disorder or reducing or inhibiting bone loss associated with a bone related disorder, comprising administering to a mammal, including man, in need of such treatment or inhibition, an effective amount of the formulation of claim 1.

B3

18. (Once amended) The method according to claim 17, wherein the bone related disorder is osteoporosis.

Please add the following new claims:

19. (New) The pharmaceutical formulation of claim 9, further comprising a preservative.

20. (New) The pharmaceutical formulation of claim 19, wherein the preservative is benzyl alchohol, m-cresol or EDTA.

B4

21. (New) The pharmaceutical formulation of claim 9, wherein the parathyroid hormone is human recombinant parathyroid hormone.

22. (New) The pharmaceutical formulation of claim 9, wherein the parathyroid hormone is human full-length parathyroid hormone.

23. (New) The pharmaceutical formulation of claim 9, wherein the pH of the citrate buffer is between 5 and 6.

24. (New) A pharmaceutical formulation comprising 1 to 3 mg/ml parathyroid hormone, 2 to 5 mg/ml NaCl, 20 to 50 mg/ml mannitol, 5 to 10 mM citrate buffer at a pH between 4 and 6, and a preservative.

25. (New) The pharmaceutical formulation of claim 24, wherein the preservative is benzyl alchohol, m-cresol or EDTA.

26. (New) The pharmaceutical formulation of claim 24, wherein the parathyroid hormone is human recombinant parathyroid hormone.

B4

27. (New) The pharmaceutical formulation of claim 24, wherein the parathyroid hormone is human full-length parathyroid hormone.

28. (New) The pharmaceutical formulation of claim 24, wherein the pH of the citrate buffer is between 5 and 6.

29. (New) A process for preparing the pharmaceutical formulation of claim 9, comprising dissolving in the citrate buffer (i) the parathyroid hormone, (ii) the mannitol, and (iii) the NaCl.

30. (New) A process for preparing the pharmaceutical formulation of claim 24, comprising dissolving in the citrate buffer (i) the parathyroid hormone, (ii) the mannitol, (iii) the NaCl, and (iv) the preservative.

31. (New) The method of claim 1, wherein the concentration of the NaCl is between 2 to 5 mg/ml.

32. (New) The pharmaceutical formulation of claim 1, wherein the parathyroid hormone is human recombinant parathyroid hormone (1-84).

33. (New) The pharmaceutical formulation of claim 9, wherein the parathyroid hormone is human recombinant parathyroid hormone (1-84).

34. (New) The pharmaceutical formulation of claim 24, wherein the parathyroid hormone is human recombinant parathyroid hormone (1-84).

35. (New) A method for treating a bone related disorder or reducing or inhibiting bone loss associated with a bone related disorder, comprising administering to a mammal, including man, in need of such treatment or inhibition, an effective amount of the formulation of claim 9.

36. (New) The method according to claim 35, wherein the bone related disorder is osteoporosis.